Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Therapy with Bevacizumab, Everolimus and TKI in mRCC
NCT01731158Phase 2Completed
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Oct 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Central European Society for Anticancer Drug Research. Primary endpoint: Progression Free Survival rate at 6 months. Started Oct 2012; status: completed.
02
Drugs
everolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01731158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731158.